Latest Breaking News On - Duke cancer institute center - Page 5 : comparemela.com

Astellas and Pfizer s XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study

Astellas and Pfizer s XTANDI® (enzalutamide) Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer in Phase 3 ARCHES Study
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesAndrew armstrongAmerican society of clinical oncologyLab abnormalitiesExchange commissionProstate cancer working groupAstellas pharma incPfizer incEuropean unionMedivation incDuke cancer institute centerCancer biologyDuke cancer instituteUrologic cancersClinical oncology

Astellas and Pfizer s XTANDI Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer

Astellas and Pfizer s XTANDI Reduced Risk of Death by 34% in Men with Metastatic Hormone-Sensitive Prostate Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

North carolinaUnited statesKenji yasukawaAndrew armstrongEuropean society for medical oncology congressEuropean commissionLab abnormalitiesProstate cancer working groupAstellas pharma incPfizer incEuropean unionEuropean society for medical oncologyDuke cancer institute centerEuropean societyMedical oncology congressAstellas pharma

EC approval for enzalutamide for men with metastatic hormone-sensitive prostate cancer

EC approval for enzalutamide for men with metastatic hormone-sensitive prostate cancer
imt.ie - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from imt.ie Daily Mail and Mail on Sunday newspapers.

Andrew armstrongAstellas pharmaAndrew krivoshikOncology developmentEuropean commissionDuke cancer institute centerCancer biologyDuke cancer instituteUrologic cancersSenior vice presidentGlobal therapeutic area headஆண்ட்ரூ ஆம்ஸ்ட்ராங்புற்றுநோயியல் வளர்ச்சிஐரோப்பிய தரகுடியூக் புற்றுநோய் நிறுவனம் மையம்புற்றுநோய் உயிரியல்

Mutations in Circulating Tumor Cells May Predict Clinical Outcomes in Patients with Metastatic Castrate-resistant Prostate Cancer

PHILADELPHIA – Various genetic alterations in circulating tumor cells (CTCs) were associated with clinical outcomes and resistance to hormone therapy in patients with metastatic castrate-resistant prostate cancer (mCRPC), according to results published in Molecular Cancer Research , a journal of the American Association for Cancer Research.

United statesAndrew armstrongGenentech rocheJohns hopkins universityUrologic cancers at duke universityMolecular cancer researchUniversity of chicagoConstellation pharmaceuticalsBristol myers squibbDuke cancer institute centerNational comprehensive cancer networkNational institutes of healthGlobal treatment sciences challenge awardAmerican association for cancer researchWeill medical college of cornell universityProstate cancer foundation

Astellas Xtandi bags additional MHRA approval in prostate cancer

Once-daily oral Xtandi approved for the treatment of adult men with metastatic hormone-sensitive prostate cancer - News - PharmaTimes

United kingdomAndrew armstrongAndrew krivoshikRegulatory agencyDuke cancer institute centerDuke cancer instituteUrologic cancersProstate cancerஒன்றுபட்டது கிஂக்டம்ஆண்ட்ரூ ஆம்ஸ்ட்ராங்டியூக் புற்றுநோய் நிறுவனம் மையம்டியூக் புற்றுநோய் நிறுவனம்சிறுநீரக புற்றுநோய்கள்